Clinical Trials Logo

Clinical Trial Summary

Open label, parallel-group, single site, 5 treatment-period study with 4 dose levels of DCCR, 1 of which is administered both with and without food.


Clinical Trial Description

Open label, parallel-group, single site, 5 treatment-period study with 4 dose levels of DCCR, 1 of which is administered both with and without food, with a 10 Day washout period between treatments. There will be 8 treatment sequences with 4 subjects randomized to each. ;


Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT02893618
Study type Interventional
Source Essentialis, Inc.
Contact
Status Not yet recruiting
Phase Phase 2
Start date July 2017
Completion date December 2017

See also
  Status Clinical Trial Phase
Recruiting NCT03458416 - A Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Patients With Prader-Willi Syndrome Phase 2
Recruiting NCT03718416 - Natural History Study of Serious Medical Events in PWS
Not yet recruiting NCT03848481 - CBDV vs Placebo in Children With Prader-Willi Syndrome (PWS) Phase 2
Terminated NCT02179151 - Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome Phase 3
Not yet recruiting NCT02205450 - Experience With Growth Hormone (GH) in Children Under 2 Years With Prader-Willi Syndrome (PWS) in the Pediatric Endocrine Department of the Hospital of Sabadell N/A
Completed NCT00375089 - Characteristics of Prader-Willi Syndrome and Early-onset Morbid Obesity N/A
Completed NCT00004351 - Study of Phenotype and Genotype Correlations in Patients With Contiguous Gene Deletion Syndromes N/A
Recruiting NCT03031626 - Oxygen Versus Medical Air for Treatment of CSA in Prader Will Syndrome Phase 4
Active, not recruiting NCT02629991 - Oxytocin vs. Placebo for the Treatment Hyperphagia in Children and Adolescents With Prader-Willi Syndrome Phase 2
Recruiting NCT02297022 - Deep Brain Stimulation for the Treatment of Obesity in Patients With Prader-Willi Syndrome Phase 1
Not yet recruiting NCT02263781 - PREPL in Health and Disease N/A
Recruiting NCT00551343 - Gut Derived Hormones, Body Composition and Metabolism in Prader-Willi Syndrome N/A
Recruiting NCT03714373 - Open-Label Extension Study of Diazoxide Choline in Patients With Prader-Willi Syndrome Phase 3
Recruiting NCT03114371 - Oxytocin Intranasal Administrations in Children With Prader-Willi Syndrome Aged From 3 to 12 Years N/A
Completed NCT00705172 - Retrospective Observational Study on Efficacy and Safety of Norditropin® in Children With Prader-Willi Syndrome N/A
Recruiting NCT03649477 - Phase 3 Study of Intranasal Carbetocin (LV-101) in Patients With Prader-Willi Syndrome Phase 3
Recruiting NCT03101826 - Optimizing the Social Engagement System in Prader-Willi Syndrome: Insights From the Polyvagal Theory N/A
Recruiting NCT03440814 - A Study of Diazoxide Choline in Patients With Prader-Willi Syndrome Phase 3
Enrolling by invitation NCT03324906 - Effects of Transcranial Direct Current Stimulation (tDCS) on Individuals With Prader-Willi Syndrome N/A
Not yet recruiting NCT03831425 - Mitochondrial Complex I Dysfunction in PWS Phase 3